Last reviewed · How we verify

Intradialytic parenteral nutrition

EZUS-LYON 1 · FDA-approved active Small molecule

Intradialytic parenteral nutrition is a Nutritional supplement / parenteral nutrition formulation Small molecule drug developed by EZUS-LYON 1. It is currently FDA-approved for Protein-energy wasting in hemodialysis patients with inadequate oral nutritional intake, Malnutrition in end-stage renal disease patients undergoing maintenance hemodialysis.

Intradialytic parenteral nutrition (IDPN) delivers intravenous amino acids, dextrose, and lipids directly into the bloodstream during hemodialysis sessions to supplement nutritional intake in malnourished dialysis patients.

Intradialytic parenteral nutrition (IDPN) delivers intravenous amino acids, dextrose, and lipids directly into the bloodstream during hemodialysis sessions to supplement nutritional intake in malnourished dialysis patients. Used for Protein-energy malnutrition in hemodialysis patients, Nutritional supplementation in end-stage renal disease patients unable to meet nutritional requirements orally.

At a glance

Generic nameIntradialytic parenteral nutrition
SponsorEZUS-LYON 1
Drug classNutritional supplement / parenteral nutrition formulation
ModalitySmall molecule
Therapeutic areaNephrology / Renal disease
PhaseFDA-approved

Mechanism of action

IDPN is administered through the venous line of the dialysis circuit during treatment, allowing simultaneous delivery of macronutrients while waste removal occurs. This approach bypasses the gastrointestinal tract and provides concentrated nutrition to patients with inadequate oral intake or protein-energy wasting, a common complication of end-stage renal disease. The timing during dialysis optimizes nutrient delivery while minimizing additional vascular access requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intradialytic parenteral nutrition

What is Intradialytic parenteral nutrition?

Intradialytic parenteral nutrition is a Nutritional supplement / parenteral nutrition formulation drug developed by EZUS-LYON 1, indicated for Protein-energy wasting in hemodialysis patients with inadequate oral nutritional intake, Malnutrition in end-stage renal disease patients undergoing maintenance hemodialysis.

How does Intradialytic parenteral nutrition work?

Intradialytic parenteral nutrition (IDPN) delivers intravenous amino acids, dextrose, and lipids directly into the bloodstream during hemodialysis sessions to supplement nutritional intake in malnourished dialysis patients.

What is Intradialytic parenteral nutrition used for?

Intradialytic parenteral nutrition is indicated for Protein-energy wasting in hemodialysis patients with inadequate oral nutritional intake, Malnutrition in end-stage renal disease patients undergoing maintenance hemodialysis.

Who makes Intradialytic parenteral nutrition?

Intradialytic parenteral nutrition is developed and marketed by EZUS-LYON 1 (see full EZUS-LYON 1 pipeline at /company/ezus-lyon-1).

What drug class is Intradialytic parenteral nutrition in?

Intradialytic parenteral nutrition belongs to the Nutritional supplement / parenteral nutrition formulation class. See all Nutritional supplement / parenteral nutrition formulation drugs at /class/nutritional-supplement-parenteral-nutrition-formulation.

What development phase is Intradialytic parenteral nutrition in?

Intradialytic parenteral nutrition is FDA-approved (marketed).

What are the side effects of Intradialytic parenteral nutrition?

Common side effects of Intradialytic parenteral nutrition include Hyperglycemia, Hypertriglyceridemia, Vascular access complications, Infection at access site, Electrolyte imbalances.

Related